Life Sciences

DOJ sues Forest for False Claims Act violations

Pharma Compliance Alert, March 4, 2009

Forest Laboratories allegedly improperly marketed its antidepressants Celexa and Lexapro for unapproved pediatric use and paid kickbacks to induce physicians to prescribe the drugs, according to a Department of Justice (DOJ) release.

The company’s illegal promotional practices surrounding Celexa and Lexapro caused thousands of false and fraudulent claims to be submitted to federal healthcare programs, the DOJ alleged.

Read more about the False Claims Act allegaions against Forest.

Most Popular